1. Home
  2. MCRB vs MIMI Comparison

MCRB vs MIMI Comparison

Compare MCRB & MIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • MIMI
  • Stock Information
  • Founded
  • MCRB 2010
  • MIMI 2018
  • Country
  • MCRB United States
  • MIMI Hong Kong
  • Employees
  • MCRB N/A
  • MIMI N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • MIMI
  • Sector
  • MCRB Health Care
  • MIMI
  • Exchange
  • MCRB Nasdaq
  • MIMI NYSE
  • Market Cap
  • MCRB 141.9M
  • MIMI 139.9M
  • IPO Year
  • MCRB 2015
  • MIMI 2025
  • Fundamental
  • Price
  • MCRB $0.72
  • MIMI $5.34
  • Analyst Decision
  • MCRB Hold
  • MIMI
  • Analyst Count
  • MCRB 5
  • MIMI 0
  • Target Price
  • MCRB $4.00
  • MIMI N/A
  • AVG Volume (30 Days)
  • MCRB 840.7K
  • MIMI 195.9K
  • Earning Date
  • MCRB 03-13-2025
  • MIMI 01-01-0001
  • Dividend Yield
  • MCRB N/A
  • MIMI N/A
  • EPS Growth
  • MCRB N/A
  • MIMI N/A
  • EPS
  • MCRB 0.00
  • MIMI 0.04
  • Revenue
  • MCRB N/A
  • MIMI $4,382,996.00
  • Revenue This Year
  • MCRB N/A
  • MIMI N/A
  • Revenue Next Year
  • MCRB N/A
  • MIMI N/A
  • P/E Ratio
  • MCRB $824.00
  • MIMI $162.31
  • Revenue Growth
  • MCRB N/A
  • MIMI 63.94
  • 52 Week Low
  • MCRB $0.54
  • MIMI $3.83
  • 52 Week High
  • MCRB $1.53
  • MIMI $6.84
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 46.92
  • MIMI N/A
  • Support Level
  • MCRB $0.69
  • MIMI N/A
  • Resistance Level
  • MCRB $0.76
  • MIMI N/A
  • Average True Range (ATR)
  • MCRB 0.05
  • MIMI 0.00
  • MACD
  • MCRB 0.00
  • MIMI 0.00
  • Stochastic Oscillator
  • MCRB 53.55
  • MIMI 0.00

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About MIMI MINT INCORPORATION LIMITED

Mint Inc Ltd is a Hong Kong-based interior design and fit-out works provider. It strategically focuses on providing integrated and industry-specific interior design and fit-out works for commercial properties. The company's work encompasses offices of different industries and various kinds of retail stores to reflect its customers' corporate values and conceptualize its customers' brands. Its commercial projects cover internationally-renowned retail stores, food and beverage outlet chains, offices, and other premises of a charitable organization in Hong Kong. It also provides integrated interior design and fit-out works for luxury residential properties to enhance the interior space's aesthetics and functionality.

Share on Social Networks: